Aetna Provides Coverage for VeriStrat NSCLC Test
The blood-based proteomic test for patients with non-small cell lung cancer is now covered by three major national payers for a total of over 160 million covered lives.
Read More
Search Results for: lung cancer
NCCN Guidelines Recommend VeriStrat Testing for NSCLC
Biodesix recently announced the inclusion of its VeriStrat profiling test in updated evidence-based, consensus-driven NCCN Guidelines for managing non-small-cell lung cancer.
Read More
Highmark Insurance Company Announces Coverage for VeriStrat Assay
One of the largest insurance companies in the United States, Highmark has announced it will begin providing coverage of the VeriStrat assay to guide second-line treatment decisions for patients with non-small cell lung cancer. Coverage takes effect on October 27, 2014.
Read MoreBiomarker- and Receptor-Targeted Therapies for NSCLC Gain Higher Success
An analysis of past clinical trials in the development of advanced therapies for non-small cell lung cancer suggests that success can be improved if identified biomarkers or receptors are used as the targets of the drug.
Read More
Product News: January 2014
New products include the Cytation 3 cell imaging multi-mode reader by BioTek and the myPlan Lung Cancer test from Myriad.
Read More